“Peanut Allergy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Peanut Allergy market. A detailed picture of the Peanut Allergy pipeline landscape is provided, which includes the disease overview and Peanut Allergy treatment guidelines. The assessment part of the report embraces in-depth Peanut Allergy commercial assessment and clinical assessment of the Peanut Allergy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The launch of the emerging therapies is expected to significantly impact Peanut Allergy treatment scenario in the upcoming years:- Drugs covered

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Peanut Allergy Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Peanut Allergy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Peanut Allergy across the complete product development cycle, including all clinical and nonclinical stages.

It comprises of detailed profiles of Peanut Allergy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details

Detailed Peanut Allergy research and development progress and trial details, results wherever available, are also included in the pipeline study.

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Peanut Allergy.

Report highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Peanut Allergy.

In the coming years, the Peanut Allergy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

A detailed portfolio of major pharma players who are involved in fueling the Peanut Allergy treatment market. Several potential therapies for Peanut Allergy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Peanut Allergy market size in the coming years.

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Peanut Allergy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

The Peanut Allergy epidemiology covered in the report provides historical as well as forecasted Peanut Allergy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.